Tobias Menne Haematologist Newcastle

Tobias Menne Haematologist Newcastle

Tobias Menne Haematologist Newcastle leads the field in acute lymphoblastic leukaemia, lymphoma, and CAR-T cell therapies. He also serves as the Clinical Director for Research, driving innovation across the Newcastle upon Tyne Hospitals NHS Foundation Trust. His leadership inspires both colleagues and patients, while his work transforms the future of haemato-oncology.

Career and Education

Dr Tobias Menne studied Medicine at the Free University in Berlin, where he built a strong foundation in clinical medicine. He then continued specialist training in haematology in the UK at St Thomas’ Hospital, Ipswich Hospital, and Addenbrooke’s Hospital in Cambridge. In 2006, he completed a PhD at Cambridge University under the supervision of Professor Alan Warren. Afterwards, he expanded his expertise in Boston, USA, working for four years at Harvard Children’s Hospital as a post-doctoral researcher in Professor Stuart Orkin’s laboratory. His return to the UK marked a new chapter when he joined Freeman Hospital in Newcastle as a Consultant Haematologist in 2010.

Leadership in Research

Since September 2021, Dr Tobias Menne has held the role of Clinical Director for Research at the Trust. In this role, he supports regional and national research in haemato-oncology. He also acts as the sub-speciality research lead, clinical haem/onc research lead, and lead for immune effector cell therapy. His influence extends across the UK through membership in national groups such as the Lymphoma Clinical Study Group, the Low and High Grade Lymphoma Working Groups, and the Adult Acute Lymphoblastic Leukaemia Working Group.

Tobias Menne Haematologist Newcastle: Research Focus

Research defines Dr Menne’s career. He dedicates significant time to clinical trials in lymphoma and acute lymphoblastic leukaemia. As Chief Investigator, he directs studies such as TIDaL, which tests ibrutinib and rituximab therapy in PTLD, and SELUDex, which investigates Selumetinib in relapsed or refractory ALL. He also contributes to major national trials, including UKALL14, PETReA, UKALL15, and POLARICE. Furthermore, he serves as Principal Investigator on several CAR-T cell therapy studies in both lymphoma and myeloma.

Special Interests and Expertise

Dr Tobias Menne focuses on acute lymphoblastic leukaemia, lymphoma, CAR-T cell therapies, and clinical research. He combines deep medical knowledge with a drive to improve treatments for patients. His leadership, research, and special interests bring hope to patients while advancing the global understanding of haematology.